CICC: Maintains outperform rating on PRADA (01913), but lowers net profit forecast.
Due to increased competition, the company has lowered its revenue forecast for next year by 9.6% to 6.155 billion euros, with EBIT and net profit forecasts for the period reduced by 13.2% and 14.1% respectively, to 1.492 billion and 976 million euros.
CICC released a research report stating that PRADA (01913) third-quarter revenue increased by 9% when calculated at a fixed exchange rate, with a total sales of 1.33 billion euros, slightly exceeding market expectations. The bank maintained a "outperform" rating on PRADA with a target price of 75 Hong Kong dollars.
The bank indicated that due to adverse foreign exchange impacts on PRADA and the expected additional loans needed for the acquisition of Versace, financial costs have increased, leading to a corresponding downward revision of the net profit forecast for this year by 7.5% to 880 million euros. The bank also adjusted PRADA's revenue and EBIT forecasts for this year by 6.1% and 6.9% to 5.731 billion and 1.359 billion euros, respectively. Due to intensified competition, the bank lowered its revenue forecast for next year by 9.6% to 6.155 billion euros, with the EBIT and net profit forecasts for the period being reduced by 13.2% and 14.1% to 1.492 billion and 976 million euros, respectively.
Related Articles

CANSINOBIO (06185): Zuo Min and Ji Xuefeng nominated as independent non-executive director candidates.

Preview of US Stock Market | Three major stock index futures rose together, and progress was made in the China-US trade negotiations.

CHINARES PHARMA(03320): China Resources Boya Bio-pharmaceutical Group's net profit for the first three quarters was 343 million yuan, a decrease of 16.8% year-on-year.
CANSINOBIO (06185): Zuo Min and Ji Xuefeng nominated as independent non-executive director candidates.

Preview of US Stock Market | Three major stock index futures rose together, and progress was made in the China-US trade negotiations.

CHINARES PHARMA(03320): China Resources Boya Bio-pharmaceutical Group's net profit for the first three quarters was 343 million yuan, a decrease of 16.8% year-on-year.

RECOMMEND

Why European Automakers Are Opposing Dutch Sanctions
20/10/2025

Domestic Commercial Rockets Enter Batch Launch Era: Behind the Scenes a Sixfold Cost Gap and Reusability as the Key Breakthrough
20/10/2025

Multiple Positive Catalysts Lift Tech Stocks; UBS Elevates China Tech to Most Attractive, Citing AI as Core Rationale
20/10/2025


